Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17242212
Andreozzi F, et al. (2007) Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 27, 2372-83 17242212
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
PD98059 IL-6 inhibit treatment-induced decrease
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
siRNA IL-6 JNK1 (human), JNK2 (human) inhibit treatment-induced decrease
siRNA IL-6 ERK1 (human), ERK2 (human) inhibit treatment-induced decrease
IL-6 no change compared to control

T495-p - eNOS (human)
Modsite: TGITRKKtFKEVANA SwissProt Entrez-Gene
Orthologous residues
eNOS (human): T495‑p, eNOS (mouse): T494‑p, eNOS (rat): T494‑p, eNOS (rabbit): T501‑p, eNOS (pig): T497‑p, eNOS (cow): T497‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin decrease
IL-6 insulin inhibit treatment-induced decrease
calyculin_A insulin inhibit treatment-induced decrease
LY294002 insulin inhibit treatment-induced decrease
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
PD98059 IL-6 inhibit treatment-induced increase
IL-6 no change compared to control

S1177-p - eNOS (human)
Modsite: TSRIRtQsFsLQERQ SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
PD98059 IL-6 inhibit treatment-induced decrease
siRNA IL-6 JNK1 (human), JNK2 (human) inhibit treatment-induced decrease
siRNA IL-6 ERK1 (human), ERK2 (human) inhibit treatment-induced decrease
IL-6 no change compared to control

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

Y210-p - ERK1 (human)
Modsite: EyVAtRWyrAPEIML SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y210‑p, ERK1 iso2 (human): Y210‑p, ERK1 iso3 (human): Y210‑p, ERK1 (mouse): Y211‑p, ERK1 (rat): Y211‑p, ERK1 (hamster): Y200‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

Y999-p - INSR (human)
Modsite: yASSNPEyLSASDVF SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y999‑p, INSR iso2 (human): Y987‑p, INSR (mouse): Y989‑p, INSR (rat): Y1000‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
PD98059 IL-6 inhibit treatment-induced decrease
IL-6 no change compared to control

Y1185-p - INSR (human)
Modsite: FGMTRDIyEtDyyRk SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1185‑p, INSR iso2 (human): Y1173‑p, INSR (mouse): Y1175‑p, INSR (rat): Y1186‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
PD98059 IL-6 inhibit treatment-induced decrease
IL-6 no change compared to control

Y1189-p - INSR (human)
Modsite: RDIyEtDyyRkGGkG SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1189‑p, INSR iso2 (human): Y1177‑p, INSR (mouse): Y1179‑p, INSR (rat): Y1190‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
PD98059 IL-6 inhibit treatment-induced decrease
IL-6 no change compared to control

Y1190-p - INSR (human)
Modsite: DIyEtDyyRkGGkGL SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1190‑p, INSR iso2 (human): Y1178‑p, INSR (mouse): Y1180‑p, INSR (rat): Y1191‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
PD98059 IL-6 inhibit treatment-induced decrease
IL-6 no change compared to control

S312-p - IRS1 (human)
Modsite: tEsItAtsPAsMVGG SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S312‑p, IRS1 (mouse): S307‑p, IRS1 (rat): S307‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 no effect upon treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
insulin IL-6 no effect upon treatment-induced increase
siRNA insulin JNK1 (human), JNK2 (human) inhibit treatment-induced increase
insulin decrease

Y612-p - IRS1 (human)
Modsite: tLHtDDGyMPMsPGV SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): Y612‑p, IRS1 (mouse): Y608‑p, IRS1 (rat): Y608‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
PD98059 IL-6 inhibit treatment-induced decrease
IL-6 no change compared to control
JNK_inhibitor_I, IL-6 no change compared to control
insulin IL-6, JNK_inhibitor_I increase

S616-p - IRS1 (human)
Modsite: DDGyMPMsPGVAPVP SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S616‑p, IRS1 (mouse): S612‑p, IRS1 (rat): S612‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase
insulin IL-6 no effect upon treatment-induced increase
siRNA insulin ERK1 (human), ERK2 (human) inhibit treatment-induced increase
insulin no change compared to control

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 no effect upon treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 no effect upon treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 no effect upon treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 no effect upon treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
insulin increase
IL-6 insulin augment treatment-induced increase

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse

S1176-p - eNOS (mouse)
Modsite: TSRIRtQsFsLQERQ SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IL-6 insulin inhibit treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced decrease
PD98059 IL-6 inhibit treatment-induced decrease
IL-6 no change compared to control

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase

Y211-p - ERK1 (mouse)
Modsite: EyVAtRWyRAPEIML SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y210‑p, ERK1 iso2 (human): Y210‑p, ERK1 iso3 (human): Y210‑p, ERK1 (mouse): Y211‑p, ERK1 (rat): Y211‑p, ERK1 (hamster): Y200‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase

S307-p - IRS1 (mouse)
Modsite: tEsITAtsPAsMVGG SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S312‑p, IRS1 (mouse): S307‑p, IRS1 (rat): S307‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 no effect upon treatment-induced increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase

S612-p - IRS1 (mouse)
Modsite: DDGyMPMsPGVAPVP SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S616‑p, IRS1 (mouse): S612‑p, IRS1 (rat): S612‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
PD98059 IL-6 inhibit treatment-induced increase
JNK_inhibitor_I IL-6 no effect upon treatment-induced increase

T183-p - JNK1 (mouse)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
PD98059 IL-6 no effect upon treatment-induced increase

Y185-p - JNK1 (mouse)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
PD98059 IL-6 no effect upon treatment-induced increase

T183-p - JNK2 (mouse)
Modsite: ACTNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
PD98059 IL-6 no effect upon treatment-induced increase

Y185-p - JNK2 (mouse)
Modsite: TNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  aorta
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase
JNK_inhibitor_I IL-6 inhibit treatment-induced increase
PD98059 IL-6 no effect upon treatment-induced increase